JP2023505301A5 - - Google Patents
Info
- Publication number
- JP2023505301A5 JP2023505301A5 JP2022534233A JP2022534233A JP2023505301A5 JP 2023505301 A5 JP2023505301 A5 JP 2023505301A5 JP 2022534233 A JP2022534233 A JP 2022534233A JP 2022534233 A JP2022534233 A JP 2022534233A JP 2023505301 A5 JP2023505301 A5 JP 2023505301A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cell
- lymphoma
- acute lymphoblastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944876P | 2019-12-06 | 2019-12-06 | |
| US62/944,876 | 2019-12-06 | ||
| PCT/CA2020/051668 WO2021108918A1 (en) | 2019-12-06 | 2020-12-04 | Treatment for acute myeloid leukemia or myelodysplastic syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505301A JP2023505301A (ja) | 2023-02-08 |
| JP2023505301A5 true JP2023505301A5 (enExample) | 2023-12-11 |
Family
ID=76221282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534233A Pending JP2023505301A (ja) | 2019-12-06 | 2020-12-04 | 急性骨髄性白血病または骨髄異形成症候群に対する治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12533357B2 (enExample) |
| EP (1) | EP4069246A4 (enExample) |
| JP (1) | JP2023505301A (enExample) |
| KR (1) | KR20220124177A (enExample) |
| CN (1) | CN115397429A (enExample) |
| AU (1) | AU2020396807B2 (enExample) |
| BR (1) | BR112022011052A2 (enExample) |
| CA (1) | CA3163796A1 (enExample) |
| IL (1) | IL293623A (enExample) |
| MX (1) | MX2022006910A (enExample) |
| TW (1) | TWI880995B (enExample) |
| WO (1) | WO2021108918A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| TWI926033B (zh) | 2021-05-11 | 2026-05-21 | 美商歐瑞克製藥公司 | 類ｐｏｌｏ激酶４抑制劑 |
| TW202333712A (zh) * | 2021-12-22 | 2023-09-01 | 加拿大健康網路大學 | 於急性骨髓性白血病或淋巴瘤之治療 |
| CN117180295A (zh) * | 2023-09-13 | 2023-12-08 | 华东医院 | 一种用于治疗tp53突变髓系肿瘤的药物组合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010115279A1 (en) | 2009-04-06 | 2010-10-14 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| TWI516262B (zh) | 2010-04-06 | 2016-01-11 | 健康網路大學 | 激酶抑制劑及以其治療癌症的方法 |
| CA2803446C (en) * | 2010-07-02 | 2019-06-04 | University Health Network | Use of plk4 antagonists for treating pten mutant diseases |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| EP3052102B1 (en) | 2013-10-04 | 2019-12-04 | Aptose Biosciences Inc. | Compositions for treating cancers |
| TR201902875T4 (tr) * | 2013-10-18 | 2019-03-21 | Univ Health Network | Plk-4 inhibitörünün tuz ve kristal formları. |
| WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| KR20190129889A (ko) | 2017-03-31 | 2019-11-20 | 노파르티스 아게 | 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법 |
| JP7343483B2 (ja) * | 2017-09-08 | 2023-09-12 | ユニバーシティー ヘルス ネットワーク | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
| US11612604B2 (en) * | 2017-12-06 | 2023-03-28 | Ludwig Institute For Cancer Research Ltd | Methods of treating cancer with PLK4 inhibitors |
| EP3959209A4 (en) | 2019-04-24 | 2022-12-28 | University Health Network | S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE |
-
2020
- 2020-12-04 KR KR1020227023046A patent/KR20220124177A/ko active Pending
- 2020-12-04 CA CA3163796A patent/CA3163796A1/en active Pending
- 2020-12-04 JP JP2022534233A patent/JP2023505301A/ja active Pending
- 2020-12-04 AU AU2020396807A patent/AU2020396807B2/en active Active
- 2020-12-04 US US17/782,632 patent/US12533357B2/en active Active
- 2020-12-04 WO PCT/CA2020/051668 patent/WO2021108918A1/en not_active Ceased
- 2020-12-04 IL IL293623A patent/IL293623A/en unknown
- 2020-12-04 MX MX2022006910A patent/MX2022006910A/es unknown
- 2020-12-04 BR BR112022011052A patent/BR112022011052A2/pt unknown
- 2020-12-04 TW TW109142965A patent/TWI880995B/zh active
- 2020-12-04 CN CN202080095784.4A patent/CN115397429A/zh active Pending
- 2020-12-04 EP EP20895810.8A patent/EP4069246A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507938A5 (enExample) | ||
| JP2012521435A5 (enExample) | ||
| ES2629317T3 (es) | Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina | |
| JP2022009090A5 (enExample) | ||
| JP2023541432A5 (enExample) | ||
| Verschraegen et al. | Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. | |
| JP2015212268A5 (enExample) | ||
| JP2022124458A5 (enExample) | ||
| JP2021100937A5 (enExample) | ||
| JP2004519493A5 (enExample) | ||
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| JP2022526850A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| JP2005512995A5 (enExample) | ||
| JP2005506367A5 (enExample) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2005509662A5 (enExample) | ||
| JP2011515481A (ja) | 癌の処置のための方法および組成物 | |
| JP2018516936A5 (enExample) | ||
| JP2024542984A5 (enExample) | ||
| JP2022551691A5 (enExample) | ||
| JP2021534160A5 (enExample) | ||
| JP2021522246A5 (enExample) | ||
| JP2022502498A5 (enExample) | ||
| JP2023537921A5 (enExample) |